|1.||Krams, Michael: 5 articles (01/2006 - 07/2003)|
|2.||Marshall, Scott: 2 articles (01/2006 - 08/2005)|
|3.||James, Ian: 2 articles (01/2006 - 08/2005)|
|4.||Macintyre, Fiona: 2 articles (01/2006 - 08/2005)|
|5.||Lees, Kennedy R: 2 articles (11/2003 - 07/2003)|
|6.||Jonsson, Niclas E: 1 article (01/2006)|
|7.||Jonsson, E Niclas: 1 article (08/2005)|
|8.||ASTIN Study Investigators: 1 article (11/2003)|
|9.||Grieve, Andrew P: 1 article (11/2003)|
|10.||Orgogozo, Jean-Marc: 1 article (11/2003)|
11/01/2003 - "ASTIN (Acute Stroke Therapy by Inhibition of Neutrophils) was an adaptive phase 2 dose-response-finding, proof-of-concept study to establish whether UK-279,276 improves recovery in acute ischemic stroke. "
11/01/2003 - "Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke."
07/01/2003 - "This was a multicenter, double-blind, dose-escalation study in 176 patients randomized to a single intravenous dose of UK-279,276 (6 cohorts: 0.06, 0.1, 0.2, 0.5, 1.0, 1.5 mg/kg) or placebo (3:1 randomization within each cohort) within 12 hours of stroke onset. "
07/01/2003 - "The purposes of this study were to evaluate the safety and tolerability of UK-279,276 and to examine its pharmacokinetics and pharmacodynamics (binding to neutrophil CD11b) in patients with acute stroke. "
01/01/2006 - "UK-279,276 binds to the CD11b/CD18 (MAC-1) on neutrophils and was under development for the treatment of ischaemic stroke. "
07/01/2003 - "UK-279,276 was well tolerated at doses up to 1.5 mg/kg. There was no evidence of a relationship between dose of UK-279,276 and adverse events or clinical chemistry or hematology laboratory tests, or of an increased incidence of infection-related adverse events with the study drug. "
11/01/2003 - "UK-279,276 was generally well tolerated, with no increased incidence of infections. "
|3.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
|5.||Brain Ischemia (Cerebral Ischemia)